| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.0039 | 1 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.00099 | 1 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.00097 | 1 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.001 | 1 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.0058 | 1 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.0067 | 1 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | Panobinostat | FIMM | pan-cancer | AAC | -0.005 | 1 |